Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
ACELYRIN, INC. ( (SLRN) ) has provided an announcement.
On January 31, 2025, ACELYRIN, INC., a biopharmaceutical company, terminated its License and Collaboration Agreement with Affibody AB, which was originally established on August 9, 2021. This agreement allowed ACELYRIN exclusive rights to develop, commercialize, and manufacture izokibep for human therapeutic uses globally, except in certain Asian countries. The termination will be effective ninety days after the notice was given, and ACELYRIN will no longer have any material financial or other obligations under this agreement.
More about ACELYRIN, INC.
YTD Price Performance: -40.0%
Average Trading Volume: 1,011,168
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $198.6M
Learn more about SLRN stock on TipRanks’ Stock Analysis page.
